Innovative Therapies for HER2-altered Non-Small Cell Lung Cancer: a Narrative Review. (PubMed, Crit Rev Oncol Hematol) - Sep 24, 2026 - "Combination strategies with immune checkpoint inhibitors, such as platinum-based chemotherapy plus PD-L1 inhibitors, are also being actively investigated, although overlapping toxicities, particularly pulmonary adverse events, remain a key concern. This narrative review summarizes the clinicopathological features of HER2-altered NSCLC, critically evaluates emerging HER2-targeted therapies, and discusses future treatment directions."
IO biomarker • Journal • Review • Gastric Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2
|
|
Andrés F Cardona; David Dávila-Dupont; Enrique Caballe-Perez; Luis Antonio Cancel Treviño; Luis Cabrera-Miranda; Mario Velasco-Córdoba; Óscar Arrieta
|